Aarti Industries Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2x0o8xct8au77w4p53qc2pau.pdf

Key Takeaways


Volume Recovery & Operating Leverage

Kotecha: "The margin's improvement was predominantly driven by operating leverage. At a contribution level, if you see at the overall product portfolio level, we remain quite consistent on the contribution margin level. But as the overall business volume goes up, the operating leverage starts kicking in and that starts getting reflected in the EBITDA percentage increase."

MMA: Peak Volumes, Tariff Headwinds & Capacity Expansion

Kotecha: "As we see based on the current situation, it feels like China has a preferred trade arrangement even than India in today's situation. We hope that will change very soon."

Zone 4: Commissioning Timeline & Strategic Logic


Capital Allocation: The Pivot to Discipline

Kotecha: "I do not think at this point in time, we are thinking about sort of the next level of large investment, which is sort of INR1,000 crore plus kind of a ticket size, which is what we did at Zone 4. I think for the next few years, the focus will remain on sort of relatively medium ticket size projects, which can be turned around quickly based on existing infrastructure, at the same time, significantly accrue to the bottom line."

End-Market & Segment Dynamics

SegmentTrendCommentary
MMA / Energy▲ Strong volumesRecord quarterly volumes; energy segment expected to settle at 30-40% of mix as Zone 4 ramps up over 1.5-2 years.
Agrochemicals▬ MixedSelect products showing volume recovery, but overall margins remain under pressure; some second-order impact from downstream customers exporting to the US. Inventory-linked pressures mostly settled.
Dyes & Pigments▼ MutedDemand growth has been muted.
Polymer▼ HeadwindFaced significant headwind as US tariffs impacted volumes.
Pharma▬ StableDomestic pharma market remains stable, providing a consistent base.
High-value Fluoro▼ PressureMargins experiencing notable challenges due to aggressive competitive pricing from China.

Innovation Pipeline: CDMO, MPP & R&D

Kotecha: "The way we look at MPP is a flexible asset, which reduces our time to market for new innovative products significantly. So it is been looked at as a capability rather than necessarily as an NC or as a net contribution engine."

Guidance & Commitments

CommitmentSpecificsTimeline
Zone 4 multipurpose plant commissioningFirst unit in Zone 4 to be commissionedQ3 FY26 (next quarter)
Calcium Chloride facility commissioningFacility to be commissionedQ3 FY26 (ongoing quarter)
MMA debottlenecking capacitySlightly increased MMA capacity from debottleneckingQ4 FY26
PEDA project commissioning4,000 TPA PEDA project in Zone 4Not specified; set to commission
Zone 4 sequential block commissioning5 incremental chemistry blocksSequentially through FY27
FY26 capexAround ₹1,000 croreFY26
FY27 capexSubstantially lower than ₹1,000 croreFY27
Debt-to-EBITDA trajectoryPotentially already peaked; should improveGoing forward
Energy segment steady-state mixSettle in 30-40% rangeEnd of 2-2.5 years
CDMO commercialisationR&D projects to large-scale manufacturing18-24 months
Cost-cutting benefit flow-throughMajor items (renewable PPAs, RM contracts) yet to flowRenewable PPAs: April 2026

Key Metrics

MetricQ2 FY26
Revenue₹2,250 cr, +21% QoQ
EBITDA₹292 cr, +36% QoQ
Profit After Tax₹106 cr, ~150% QoQ increase, after factoring in exceptional items
EBITDA margin13.0% (₹292 cr on ₹2,250 cr revenue, per analyst's math)
CAPEX (quarter)₹267 cr
CAPEX guidance (FY26)~₹1,000 cr
CAPEX guidance (FY27)Substantially lower than ₹1,000 cr
Tax rate estimate (FY27)Below 15%
Tax rate estimate (FY28)Between 15% to 20%
Energy segment revenue share43% of revenue
Export shareUpwards of 60% of revenue
Working capital cycle45–50 days
Cost optimization program₹150–200 cr in actions completed, roughly 40–50% benefit yet to flow through to bottom line
MMA capacity debottlenecking target~3 lakh tons
PEDA new capacity4,000 TPA